David Drutz - 19 Aug 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Director
Signature
/s/ Andrew Shutterly, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
19 Aug 2024
Net transactions value
-$4,172
Form type
4
Filing time
20 Aug 2024, 18:05:08 UTC
Previous filing
29 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $52,000 +20,000 +67% $2.60 49,785 19 Aug 2024 See Footnote F1, F2
transaction ALT Common Stock, par value $0.0001 Sale $54,241 -7,827 -16% $6.93 41,958 19 Aug 2024 See Footnote F2, F3
transaction ALT Common Stock, par value $0.0001 Options Exercise $54,375 +21,750 +52% $2.50 63,708 19 Aug 2024 See Footnote F1, F2
transaction ALT Common Stock, par value $0.0001 Sale $56,306 -8,184 -13% $6.88 55,524 19 Aug 2024 See Footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Options Exercise $0 -20,000 -100% $0.000000 0 19 Aug 2024 Common Stock, par value $0.0001 20,000 $2.60 Direct F4
transaction ALT Stock Options (option to buy) Options Exercise $0 -21,750 -83% $0.000000 4,350 19 Aug 2024 Common Stock, par value $0.0001 21,750 $2.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC.
F2 Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
F3 This sale represents shares sold to cover the exercise price.
F4 The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.
F5 The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney